Publications by authors named "Christian Knoop"

Article Synopsis
  • - Psoriasis is linked to lower life expectancy due to systemic inflammation, and a study analyzed the neutrophil-to-lymphocyte ratio as a marker of this inflammation during treatment with two types of biologic drugs.
  • - Results showed that the neutrophil-to-lymphocyte ratio significantly decreased within 3 months and remained low for at least 33 months, with greater reductions in patients receiving tumour necrosis factor-α antagonists compared to those on interleukin-12/23 antagonists.
  • - The findings indicate that tumour necrosis factor-α antagonist treatment and initial neutrophil-to-lymphocyte ratios are important predictors of lower cardiovascular risk during psoriasis treatment, highlighting distinct effects of different drug classes
View Article and Find Full Text PDF
Article Synopsis
  • The Psoriasis Area and Severity Index (PASI) is commonly used to evaluate psoriasis treatments, but its effectiveness as a measure of systemic disease in individual patients hasn't been systematically studied.* -
  • A retrospective study involving 186 treatments for psoriasis found weak-to-moderate correlations between PASI scores and systemic inflammation biomarkers like the neutrophil-to-lymphocyte ratio and C-reactive protein.* -
  • While PASI can indicate levels of systemic inflammation, it should not replace laboratory tests for more accurate evaluations, especially in patients with concurrent conditions like psoriatic arthritis.*
View Article and Find Full Text PDF
Article Synopsis
  • * A study showed that adding methotrexate increased the risk of mild laboratory adverse events, with notable decreases in blood cell counts and an increase in liver enzyme levels (GPT).
  • * Serious laboratory side effects (grades 3-4) were observed in about 9.5% of patients using methotrexate compared to 5.2% without it, leading to potential discontinuation of methotrexate in some cases due to these side effects.
View Article and Find Full Text PDF

Only limited data on laboratory parameter dynamics and safety under prolonged biologic treatment in a "real-world" scenario are available for recommendations on screening and monitoring. This study is a retrospective analysis of routine parameter dynamics and laboratory adverse events (LAE) in psoriasis patients on long-term treatment (n = 199) with tumour necrosis factor (TNF)-α-antagonists (adalimumab, etanercept), and the interleukin (IL)12/23-antagonist ustekinumab. Overall, neutrophil (PMN) counts (-11%) and triglycerides (+9%) changed considerably.

View Article and Find Full Text PDF

Background: Adalimumab and Etanercept are TNF-α antagonists commonly used for treatment of moderate-to-severe psoriasis and psoriatic-arthritis. Reliable instruments to assist the selection of patients for a specific treatment in a real-world scenario are unavailable.

Objective: To identify patient characteristics and baseline laboratory parameters predicting response to Adalimumab- and Etanercept-treatment.

View Article and Find Full Text PDF